首页> 外文期刊>Archives of disease in childhood >P04?Non-compartmental analysis of vancomycin pharmacokinetics in critically ill children
【24h】

P04?Non-compartmental analysis of vancomycin pharmacokinetics in critically ill children

机译:P04?重症儿童万古霉素药代动力学的非区室分析

获取原文
       

摘要

Background Vancomycin is often used as the drug of choice in the treatment of bacteria that are methicillin resistant or in patients sensitive to penicillin. This study describes the pharmacokinetics of vancomycin in critically ill children. Methods Children aged 1month to 16 years admitted to the paediatric intensive care unit of the Red Cross War Memorial Hospital and on vancomycin treatment for ≥24 hours and ≤72 hours were prospectively recruited. Blood samples were collected around predetermined optimal sampling times. A minimum of three samples per patients was analysed. Non-compartmental analysis was used to determine the volume of distribution (V), clearance (CL), half-life (tsub1/2/sub), area under the concentration-time curve (AUC), elimination constant (Ke) and Mean residence time (MRT). The minimum concentration (Cmin) and maximum concentration (Cmax) of vancomycin were measured directly as trough and peak plasma concentration respectively. Analysis of data was performed using PKNCA version 0.8.5 in R. Results Forty-nine serum concentrations from 10 patients were included in the analysis. The ratio of male to female was 1:1. Median age (Range) was 1.6 (0.2–15) years, weight = 10.6 (3.1–31.3) kg, baseline serum creatinine (Scr) = 0.31 (0.15–0.78) mg/dL. Patients received daily vancomycin doses ranging from 56 to 78 mg/kg. Mean PK parameters (range) were as follows: CL = 0.12±0.15 (0.018–0.52) L/h/kg, V =0.68±0.47 (0.15–1.57) L/kg, Ke = 0.147±0.073 (0.07–0.33) hsup-1/sup, tsub1/2/sub =5.54±2.03 (2.11–9.62) h, MRT=8.02±2.92 (3.04–13.88) h, AUC =322.07±245.65 (31.6–850.4) mg/L.h, Cmin =6.21±3.66 (2.0–14.5) mg, Cmax =38.91±31.92 (10.4–97.2) mg. Trough concentration and AUC were not met in 80% and 75% of the patients. Conclusion Variability in vancomycin pharmacokinetics was observed in patients. At current doses, target trough concentrations and AUC were not met.
机译:背景万古霉素通常用作治疗耐甲氧西林的细菌或对青霉素敏感的患者的首选药物。这项研究描述了万古霉素在危重儿童中的药代动力学。方法前瞻性招募入选为红十字战争纪念医院小儿重症监护室并接受万古霉素治疗≥24小时且≤72小时的1个月至16岁的儿童。在预定的最佳采样时间附近采集血液样本。每位患者至少分析了三个样本。使用非区室分析法确定分布体积(V),清除率(CL),半衰期(t 1/2 ),浓度-时间曲线下面积(AUC),消除常数(Ke)和平均停留时间(MRT)。万古霉素的最小浓度(Cmin)和最大浓度(Cmax)分别直接以谷浓度和谷浓度测量。在R中使用PKNCA版本0.8.5进行数据分析。结果分析了10位患者的49个血清浓度。男女之比为1:1。中位年龄(范围)为1.6(0.2-15)岁,体重= 10.6(3.1-31.3)kg,基线血清肌酐(Scr)= 0.31(0.15-0.78)mg / dL。患者每天接受的万古霉素剂量范围为56至78 mg / kg。平均PK参数(范围)如下:CL = 0.12±0.15(0.018-0.52)L / h / kg,V = 0.68±0.47(0.15-1.57)L / kg,Ke = 0.147±0.073(0.07-0.33) h -1 ,t 1/2 = 5.54±2.03(2.11-9.62)h,MRT = 8.02±2.92(3.04–13.88)h,AUC = 322.07±245.65 (31.6–850.4)mg / Lh,Cmin = 6.21±3.66(2.0–14.5)mg,Cmax = 38.91±31.92(10.4–97.2)mg。在> 80%和> 75%的患者中未达到谷浓度和AUC。结论观察到患者万古霉素药代动力学存在差异。在当前剂量下,未达到目标谷浓度和AUC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号